Email Alert | RSS    帮助

中国防痨杂志 ›› 2018, Vol. 40 ›› Issue (7): 776-780.doi: 10.3969/j.issn.1000-6621.2018.07.020

所属专题: GeneXpert MTB/RIF检测技术相关研究

• 综述 • 上一篇    下一篇

Xpert MTB/RIF Ultra与Xpert MTB/RIF检测技术的临床应用及研究进展

王淑琦,黄海荣(),王桂荣()   

  1. 101149 首都医科大学附属北京胸科医院 北京市结核病胸部肿瘤研究所 国家结核病临床实验室 耐药结核病研究北京市重点实验室
  • 收稿日期:2018-03-18 出版日期:2018-07-10 发布日期:2018-09-07
  • 通信作者: 黄海荣,王桂荣 E-mail:huanghairong@tb123.org;wangguirong1230@ccmu.edu.cn
  • 基金资助:
    国家自然科学基金项目(81703632);北京市自然科学基金(7172050);北京市科学技术委员会资助(Z171100001017065)

Clinical application and research progress of Xpert MTB/RIF Ultra and Xpert MTB/RIF tests

Shu-qi WANG,Hai-rong HUANG(),Gui-rong WANG()   

  1. National Tuberculosis Clinical Laboratory, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing 101149,China
  • Received:2018-03-18 Online:2018-07-10 Published:2018-09-07
  • Contact: Hai-rong HUANG,Gui-rong WANG E-mail:huanghairong@tb123.org;wangguirong1230@ccmu.edu.cn

摘要:

结核病(TB)是目前全球最严重的传染性疾病之一,利福平耐药实时荧光定量核酸扩增(Xpert MTB/RIF,简称“Xpert”)检测技术作为一种快速检测结核分枝杆菌(MTB)和利福平耐药性的方法,以较高的敏感度和特异度为TB的诊断和治疗提供了可靠的信息,但其本身还存在一些不足和局限。2017年3月,世界卫生组织(WHO)推荐新一代检测方法——超敏结核分枝杆菌和利福平耐药基因检测(Xpert MTB/RIF Ultra,简称“Xpert Ultra”)替代Xpert检测。与Xpert检测相比, Xpert Ultra检测对含菌量少的标本检测敏感度更高,如肺外结核、TB并发艾滋病、儿童结核病等,对于正确选择治疗药物、制定合理的治疗方案有重要的意义。作者对Xpert技术的局限性及其与Xpert Ultra的异同进行综述,为Xpert Ultra在临床中的应用提供依据。

关键词: 结核, 核酸扩增技术, 早期诊断, 综述文献(主题)

Abstract:

Tuberculosis (TB) is one of the leading infectious diseases worldwide. As a rapid nucleic acid amplification test, Xpert MTB/RIF (Xpert) assay can detect mycobacteria bacilli and rifampicin resistance simulta-neously, and provide reliable information for TB diagnosis and treatment due to its high sensitivity and specificity. However, Xpert also demonstrated some imperfections during the clinical practice. Xpert MTB/RIF Ultra (Xpert Ultra) assay is a next-generation assay of Xpert, WHO recommended it in March, 2007. In contrast to Xpert, Ultra has acquired increased sensitivity with paucibacillary specimens collected from patients with extra-pulmonary TB, TB/HIV co-infection or pediatric TB, which is of great significance for regimen establishment. In this review, the limitation of Xpert, the similarity and difference between Xpert and Xpert Ultra are discussed, which will throw light on the value of Xpert Ultra’s clinical application.

Key words: Tuberculosis, Nucleic acid amplification techniques, Early diagnosis, Review literature as topic